Wells Fargo & Company Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price

Autolus Therapeutics (NASDAQ:AUTL) had its price target lowered by investment analysts at Wells Fargo & Company from $6.00 to $5.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 170.27% from the company’s current price.

Separately, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $9.12.

Autolus Therapeutics Trading Up 0.5%

Shares of AUTL stock opened at $1.85 on Wednesday. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.00. The firm’s fifty day moving average price is $2.33 and its two-hundred day moving average price is $1.90. The firm has a market capitalization of $492.36 million, a P/E ratio of -2.20 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. As a group, equities research analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Armistice Capital LLC increased its stake in shares of Autolus Therapeutics by 9.1% during the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after purchasing an additional 1,000,000 shares during the last quarter. TFG Asset Management GP Ltd boosted its holdings in shares of Autolus Therapeutics by 10.5% during the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after buying an additional 900,000 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after buying an additional 11,289 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth about $1,288,000. Finally, Diametric Capital LP bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth about $638,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.